Skip to main content
Vaibhav Sahai, MD, Oncology, Ann Arbor, MI

VaibhavSahaiMDMS

Oncology • Ann Arbor, MI

Gastrointestinal Cancer

Associate Professor of Medicine, University of Michigan

Join to view full profile

Dr. Sahai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sahai's full profile

Already have an account?

  • Office

    University of Michigan
    1500 E Medical Center Dr., C412 MIB
    Ann Arbor, MI 48109
    Phone+1 734-647-8902
    Fax+1 734-936-4940

Summary

  • Dr. Vaibhav Sahai is an oncologist in Ann Arbor, MI and is affiliated with Michigan Medicine. He received his medical degree from Government Medical College Amritsar and has been in practice 13 years. He specializes in gastrointestinal cancer and hematologic oncology and is experienced in gastrointestinal oncology.

Education & Training

  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
  • UPMC Medical Education/Mercy
    UPMC Medical Education/MercyResidency, Internal Medicine, 2007 - 2010
  • Harvard University
    Harvard UniversityMS, Clinical Epidemiology, 2005 - 2006
  • Government Medical College Amritsar
    Government Medical College AmritsarClass of 2004

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2013 - 2026
  • IL State Medical License
    IL State Medical License 2010 - 2014
  • PA State Medical License
    PA State Medical License 2007 - 2010
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors  
    Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology

Lectures

  • Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recur... 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
  • A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresec... 
    2019 ASCO Annual Meeting - 6/1/2019
  • A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from Its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) Congress
    Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from Its Multicenter, Randomized Phase 1b/2 Trials at the 2021 European Society of Medical Oncology World Gastrointestinal (GI) CongressJune 30th, 2021
  • FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer
    FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary CancerJune 29th, 2021

Dr. Vaibhav Sahai, Dr. Vaibhav Sahai, MD, Dr. V Sahai